NASDAQ:RARE | Free Cash Flow | Ultragenyx Pharmaceutical Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2012-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$197M$1M-$198M
2025-12-31-$99.83M$938,000.00-$100.77M
2025-03-31-$166M$1M-$167M
2024-12-31-$79.32M$163,000.00-$79.48M
2024-03-31-$190.73M$3.21M-$193.94M
2023-12-31-$84.1M$1.33M-$85.43M
2023-03-31-$156.87M$25.03M-$181.9M
2022-12-31-$90.34M$26.97M-$117.31M
2022-03-31-$117.52M$32.18M-$149.71M
2021-12-31-$54.34M$16.05M-$70.39M
2021-03-31-$159.35M$16.41M-$175.76M
2020-12-31-$62.45M$21.95M-$84.4M
2020-03-31-$95.15M$14.1M-$109.25M
2019-12-31-$72.04M$11.5M-$83.54M
2019-03-31-$95.78M$3.06M-$98.83M
2018-12-31-$55.85M$1.19M-$57.05M
2018-03-31-$89.48M$475,000.00-$89.95M-297.34%
2017-12-31-$81.82M$899,000.00-$82.72M
2017-03-31-$61.21M$485,000.00-$61.69M
2016-12-31-$47.68M$666,000.00-$48.35M
2016-03-31-$44.9M$1.48M-$46.37M
2015-12-31-$40.44M$1.92M-$42.37M
2015-03-31-$17.66M$459,000.00-$18.12M
2014-12-31-$14.74M$453,000.00-$15.19M
2014-03-31-$8.34M$569,000.00-$8.91M
2013-12-31-$9.77M$129,000.00-$9.9M
2013-03-31-$6.29M$177,000.00-$6.47M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$466M$6M-$472M
2024-12-31-$414M$7M-$421M
2023-12-31-$475M$44M-$519M
2022-12-31-$380.47M$116.12M-$496.59M
2021-12-31-$338.7M$73.09M-$411.79M
2020-12-31-$132.22M$43.91M-$176.13M
2019-12-31-$345.38M$24.83M-$370.22M
2018-12-31-$290.57M$4.08M-$294.64M
2017-12-31-$253.84M$2.79M-$256.64M
2016-12-31-$160.98M$10.19M-$171.16M
2015-12-31-$105.98M$4.96M-$110.93M
2014-12-31-$44.63M$2.15M-$46.78M
2013-12-31-$31.2M$407,000.00-$31.61M
2012-12-31-$12.5M$1.09M-$13.6M